NeuroMab™ Anti-TNFR2 Antibody, Clone TNFRAB1
A functional antibody raised against Human TNFR2.
- Host Species:
- Human
- Species Reactivity:
- Human
- Applications:
- ELISA; FC; In Vitro; Inhib; In Vivo; Antagonist
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Formulation
Preservatives
Concentration
Purification
Purity
Endotoxin Level
Low Endotoxin < 1 EU/mg
Shipping
Storage
Research Use Only
Target
Official Name
Full Name
Alternative Names
Figure 1 shows the results of replicate experiments performed to determine the effect of TNFRAB2 on T-reg cell proliferation.
LIM1863 xenograft tumor growth curves during treatment with mAb avp6 3G9 (A), soluble TGFbRII-Fc-Ig fusion protein (▼) or vehicle PBS (■).
Figure 2 is a graph showing the ability of TNFRAB1 and TNFRAB2 to generally inhibit T-reg cell proliferation.
LIM1863 xenograft tumor growth curves during treatment with mAb avp6 3G9 (A), soluble TGFbRII-Fc-Ig fusion protein (▼) or vehicle PBS (■).
Figure 3 is a graph showing the effect of TNFRAB1 and TNFRAB2 on T-reg cell proliferation relative to the effect induced by IL-2 treatment.
LIM1863 xenograft tumor growth curves during treatment with mAb avp6 3G9 (A), soluble TGFbRII-Fc-Ig fusion protein (▼) or vehicle PBS (■).
Figure 4 Flow cytometry plot showing various phenotypes of the effects of drugs directing T-reg cell growth (eg, TNFα, IL-2, and TNFR2 agonists) and the TNFR2 antagonist TNFRAB2 on T-reg cell proliferation.
Treatment with a TNFR2 antagonist antibody preferentially inhibits the proliferation of CD25Hi-expressing T-reg cells. After incubation for up to 48 h with IL-2 (200 U/ml), TNFα (20 ng/ml), or TNFR2 antagonist antibody (12.5 pg/ml) alone, the proportion of CD4+, CD25Hi+ cells expressing TNFR2 is shown.
Figure 5 is a graph showing the effect of TNFR2 antagonist antibodies on TNF[alpha] and lymphotoxin expression.
Treatment with a TNFR2 antagonist antibody preferentially inhibits the proliferation of CD25Hi-expressing T-reg cells. After incubation for up to 48 h with IL-2 (200 U/ml), TNFα (20 ng/ml), or TNFR2 antagonist antibody (12.5 pg/ml) alone, the proportion of CD4+, CD25Hi+ cells expressing TNFR2 is shown.
Figure 6 is a graph showing the effect of TNFR2 antagonist antibodies on FoxP3 and CD25 expression.
Treatment with a TNFR2 antagonist antibody preferentially inhibits the proliferation of CD25Hi-expressing T-reg cells. After incubation for up to 48 h with IL-2 (200 U/ml), TNFα (20 ng/ml), or TNFR2 antagonist antibody (12.5 pg/ml) alone, the proportion of CD4+, CD25Hi+ cells expressing TNFR2 is shown.
Publications (0)
